|77.40||-0.37 / -0.48%|
Data as of 3:59pm ET
|77.32||-0.0798 / -0.10%|
The 6 analysts offering 12-month price forecasts for Alnylam Pharmaceuticals Inc have a median target of 102.00, with a high estimate of 110.00 and a low estimate of 90.00. The median estimate represents a +31.78% increase from the last price of 77.40.
The current consensus among 8 polled investment analysts is to Buy stock in Alnylam Pharmaceuticals Inc. This rating has held steady since September, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.